⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14384044 | 1.00 | — | — | |
| SCHEMBL22482815 | 0.84 | — | — | |
| SCHEMBL10296588 | 0.84 | — | — | |
| SCHEMBL18929629 | 0.80 | — | — | |
| SCHEMBL12569214 | 0.74 | — | — | |
| SCHEMBL845571 | 0.72 | — | — | |
| SCHEMBL2041110 | 0.71 | — | — | |
| SCHEMBL21813531 | 0.71 | — | — | |
| SCHEMBL257423 | 0.71 | — | — | |
| SCHEMBL1640394 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3265128-A1 | OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION | Chase Pharmaceuticals Corporation (US) | 2018-01-10 | — | — | EP | claimed |
| WO-2016144719-A1 | OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION | CHASE THOMAS N (US) | 2016-09-15 | — | — | WO | claimed |
| WO-1997020556-A9 | METHOD FOR TREATING PAIN | — | 1997-10-02 | — | — | WO | claimed |
| EP-4126840-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| US-11009749-B2 | Liquid crystal display device and method for manufacturing liquid crystal display device | SHARP KABUSHIKI KAISHA (JP) | 2021-05-18 | — | — | US | disclosed |
| EP-3347011-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Chase Pharmaceuticals Corporation (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3265128-A1 | OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION | Chase Pharmaceuticals Corporation (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-3143994-A1 | ENDOPARASITE CONTROL AGENT AND USE THEREOF | The University of Tokyo (JP) | 2017-03-22 | — | — | EP | disclosed |
| WO-2017044693-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017035348-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-9540370-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBVIE DEUTSCHLAND GMBH & CO., KG. (DE) | 2017-01-10 | — | — | US | disclosed |
| EP-2376455-B1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120172376-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-7867980-B2 | Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20100184746-A1 | LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD | 2010-07-22 | — | — | US | disclosed |
| WO-2008087421-A2 | MALE CONTRACEPTIVE | KING'S COLLEGE LONDON (GB) | 2008-07-24 | — | — | WO | disclosed |
| EP-1564259-B1 | Azo dye, colored curable composition, color filter and producing method therefor | FUJIFILM CORP (JP) | 2008-03-12 | — | — | EP | disclosed |
| EP-1316203-A2 | COMBINATION FOR TREATING PSYCHOSES, COMPRISING AN ANTIPSYCHOTIC AND A MUSCARINIC AGONIST | ELI LILLY AND COMPANY (US) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002003684-A2 | COMBINATION FOR TREATING PSYCHOSES, COMPRISING AN ANTIPSYCHOTIC AND A MUSCARINIC AGONIST | ELI LILLY AND COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| WO-1994007493-A1 | STABILIZED COMPOSITIONS CONTAINING 1,2,5,6-TETRAHYDRO-1-METHYL-3-PYRIDINECARBOXYALDEHYDE-O-METHYL-OXIME | WARNER-LAMBERT COMPANY (US) | 1994-04-14 | — | — | WO | disclosed |